FDA grants Breakthrough Therapy Designation for venetoclax in 17p deletion relapsed-refractory chronic lymphocytic leukaemia
7 May 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation for venetoclax for the treatment of people who have relapsed or refractory CLL with 17p deletion...